Lund, Sweden, September 21, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that Fredrik Röök, VP Business Development at Hansa Biopharma, will participate in the panel discussion “Breaking into New Markets: Strategies for Global Biopharma Expansion” at LSX Congress USA in Boston at 11:00 a.m. EST on Wednesday, September 23, 2026. Read more…
Winsford, UK, 16 September 2026: Advanced Medical Solutions Group plc (AIM: AMS), a world-leading specialist in tissue-healing technologies, today announces its unaudited interim results for the six months ended 30 June 2026 (the “Period”). Read more…
15 patients dosed with RTX001, an engineered Regenerative Macrophage Therapy designed to address inflammation and fibrosis EMERALD is evaluating safety and efficacy of RTX001 in patients with end-stage liver disease and a history of decompensated liver cirrhosis Interim clinical data expected in Q4 2026 Edinburgh and London, UK, 11 September 2026 – Resolution Therapeutics Limited […]
Steven Kelly appointed Chief Executive Officer to lead Actithera through clinical development and continued pipeline expansion Briggs Morrison appointed Chair of the Board, bringing extensive biotech leadership and oncology drug development expertise John Crowley appointed Independent Director, adding proven strategic, financial and capital markets leadership Oslo, Norway and Cambridge, Massachusetts — 10 September 2026 — […]
Dr. Walker joins to lead Scenic’s transition into clinical development and shape its clinical strategy Lead program SC6177 is advancing toward the clinic with a first-in-class approach to restoring lysosomal function, a key driver of multiple neurodegenerative disease Amsterdam, The Netherlands — 10 September 2026: Scenic Biotech (“Scenic” or “the Company”), a neurometabolic company whose […]
